Latest Ratios: P/E Ratio -18.7x · EV/EBITDA N/A · ROE -58.1%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $34.6B | $15.1B | $7.3B | $3.2B | $1.9B | $1.8B | $2.6B | — | — | — |
| Enterprise Value | $34.4B | $14.9B | $6.9B | $2.6B | $1.8B | $1.8B | $2.6B | — | — | — |
| P/E Ratio → | -18.69 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 175.07 | — | — | 280.24 | 54.28 | 62.35 | 61.34 | — | — | — |
| P/B Ratio | 18.96 | 9.28 | 3.24 | 1.78 | 2.80 | 3.04 | 5.55 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 227.71 | 51.54 | 60.93 | 59.68 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating Margin | — | — | — | -4207.1% | -730.0% | -639.7% | -257.5% | -108.2% | -200.0% | — |
| Net Profit Margin | — | — | — | -3768.3% | -703.0% | -636.6% | -251.6% | -95.2% | -207.2% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -58.1% | -58.1% | -29.3% | -34.8% | -38.6% | -34.7% | -34.5% | -38.3% | -82.6% | -687.0% |
| ROA | -46.1% | -46.1% | -26.0% | -30.4% | -32.1% | -28.7% | -27.5% | -24.4% | -45.0% | -206.5% |
| ROIC | -54.3% | -54.3% | -33.6% | -40.5% | -33.7% | -29.3% | -30.8% | -49.8% | -266.8% | — |
| ROCE | -53.0% | -53.0% | -32.0% | -36.5% | -36.2% | -31.4% | -31.7% | -34.1% | -54.7% | -416.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.06 | 0.05 | 0.09 | 0.11 | 0.07 | — | 0.00 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.14 | -0.18 | -0.33 | -0.14 | -0.07 | -0.15 | -0.11 | -0.72 | -2.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -45.69 | -45.69 | — | -1450.79 | — | -15589.92 | -1527.59 | -489.92 | -359.25 | -301.20 |
Net cash position: cash ($384M) exceeds total debt ($159M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.14 | 7.14 | 14.20 | 13.06 | 10.65 | 9.77 | 9.63 | 3.11 | 2.80 | 1.24 |
| Quick Ratio | 7.14 | 7.14 | 14.20 | 13.06 | 10.65 | 9.77 | 9.63 | 3.11 | 2.58 | 1.24 |
| Cash Ratio | 6.97 | 6.97 | 13.97 | 12.88 | 10.40 | 9.56 | 9.34 | 2.85 | 2.28 | 1.19 |
| Asset Turnover | — | — | — | 0.01 | 0.04 | 0.04 | 0.08 | 0.23 | 0.12 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 39.53 | 48.21 | 73.63 | 54.29 | 63.73 | 132.19 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $190M | $168M | $113M | $81M | $73M | $67M | $36M | $36M | $36M |
Includes 30+ ratios · 9 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RVMD stock.
Revolution Medicines, Inc.'s current P/E ratio is -18.7x. This places it at the 50th percentile of its historical range.
Revolution Medicines, Inc.'s return on equity (ROE) is -58.1%. The historical average is -43.9%.
Based on historical data, Revolution Medicines, Inc. is trading at a P/E of -18.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Sustained operating cash burn
Metrics are mathematically derived from official filings.
Premium Pricing Without Earnings Support
According to reported quarterly figures, RVMD trades at a P/S of 206.92 and P/B of 22.41 with a negative trailing P/E of -22.10, meaning the market is pricing a pipeline outcome rather than any current earnings or revenue base.
Traditional earnings multiples are not meaningful here because net income is negative in every period shown, so the valuation rests almost entirely on sales and book value ratios. The P/S multiple of over 200 reflects a single recent revenue print against a large equity base, which suggests investors are capitalizing future commercialization rather than observed cash generation. Investors should monitor whether the implied growth expectations remain supportable if revenue fails to recur at the 2026Q3 level.
Debt Layering Against Negative Coverage
Based on reported figures, D/E rose from 0.05 in 2024Q3 to 0.27 in 2026Q3 while interest coverage stands at -11.12, indicating borrowing has increased even though operating earnings do not cover interest expense.
Leverage remains modest in absolute terms with total debt near $639M against equity of $2.4B, yet the negative interest coverage shows debt service is not supported by operating income. The step-up in borrowing during 2026 appears to be a deliberate financing choice rather than a response to operating cash generation. Warrants further investigation into the debt maturity profile and covenant terms, which are not provided in the supplied data.
Strong Current Ratio Masks Burn Exposure
As reported in the balance sheet, the current ratio of 8.36 in 2026Q3 looks comfortable, but cash fell from $815.4M to $615.9M in one quarter, pointing to a short runway if the free cash flow deficit persists near $419M per quarter.
A current ratio above 8 and quick ratio nearly identical to it indicate that liquid assets dominate current liabilities and inventory is not a meaningful factor. However, the ratio is a snapshot that does not capture the pace of cash consumption. Based on reported figures, the quarterly burn rate suggests the headline liquidity position may overstate how long current resources can fund operations without new capital.
Working Capital Timing Distorts Burn
Based on reported quarterly data, DPO of 26,598 days and CCC of -23,390 days are not economically interpretable for this business, reflecting near-zero cost of goods rather than genuine supplier leverage.
The efficiency ratios are dominated by the absence of a meaningful cost of sales base, so DIO and DPO values are extreme and should not be read as operating advantages. Working capital swings of over $140M between quarters indicate that accrual and payable timing drives reported burn more than operating trends. Analysts should focus on the cash balance trajectory rather than these conversion metrics.
Headline Liquidity Overstates Durable Funding
Based on reported figures, the strong current ratio may lead readers to underestimate how quickly a free cash flow deficit above $400M per quarter could erode the cash balance absent new financing.
The most misleading signal in this dataset is the 8.36 current ratio, which describes the composition of the balance sheet rather than its duration. Stock-based compensation of $62.6M to $87.3M per quarter reduces the reported loss but does not reduce the cash that must be funded. Investors should treat future financing access as a central assumption that warrants monitoring rather than a given.